The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...

Ketamine therapy has become known for its effects at combating depression and other mood disorders. There’s a growing body of ...

This is due to the risks for serious adverse outcomes resulting from sedation, dissociation, respiratory depression, abuse, ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Spravato is classified as a Schedule III controlled substance and is only available through a restricted program called the Spravato REMS. The Food and Drug Administration (FDA) has approved ...

were among the most effective treatments for treatment-resistant depression, usually defined as severe depressive symptoms that have not improved despite treatment with at least two standard ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug ...